Tof MRM for the Quantification of Peptide Biomarkers in Human Glioblastoma with the Xevo™ MRT Mass Spectrometer

Significance of the Topic

Glioblastoma is a highly aggressive brain cancer with limited treatment options and poor survival rates. Precise quantification of phosphorylated peptide biomarkers is critical for understanding disease progression and evaluating novel therapies. The integration of high-resolution mass spectrometry and targeted quantitation enhances specificity and offers both qualitative and quantitative insights into protein activation pathways.

Objectives and Study Overview

This study demonstrates the application of time-of-flight multiple reaction monitoring (Tof MRM) on the Xevo MRT Mass Spectrometer for absolute quantification of phosphorylated peptides in human glioblastoma cell lines. Performance metrics were compared with traditional MRM on the Xevo TQ Absolute Mass Spectrometer to evaluate sensitivity, linear dynamic range, and quantitative accuracy.

Methodology

Four human glioblastoma cell lines, including untreated controls and samples treated with ADI-PEG20 metabolic therapy, were lysed and reduced with dithiothreitol, alkylated with iodoacetamide, and digested with trypsin. Phosphopeptides were enriched using a phosphopeptide enrichment kit, and heavy labeled peptide standards were spiked into samples and calibration digests. Separation was performed on an Evosep One system with a 30 SPD method, followed by NanoLockSpray ionization and mass spectrometry analysis in Tof MRM mode monitoring multiple transitions per precursor.

Instrumentation

• Evosep One chromatography system with Evotip Pure sample preparation.
• Xevo MRT Mass Spectrometer operating in Tof MRM mode with enhanced duty cycle.
• Xevo TQ Absolute Mass Spectrometer for comparative MRM experiments.
• NanoLockSpray ion source with 20 µm fused silica emitter.
• Waters_connect Software Platform for automated data acquisition, peak integration, and quantitation.

Main Results and Discussion

• A linear dynamic range spanning four orders of magnitude was achieved with R2 values greater than 0.99 for both platforms.
• Limits of detection and quantitation of 0.1 fmol and 1.0 fmol, respectively, were equivalent between Tof MRM and traditional MRM.
• Signal-to-noise ratios around 6:1 were observed at low-level peptide loadings (10 amol), demonstrating comparable sensitivity.
• Quantitative differences in phosphopeptide abundance were confirmed for specific markers; for example, AEEDEpS from calnexin showed a statistically significant change (p=0.0276) following treatment.

Benefits and Practical Applications

• Combines high-resolution qualitative capabilities with targeted quantitative performance in a single experiment.
• Enhanced duty cycle maximizes ion utilization for improved sensitivity in complex biological matrices.
• Automated data processing workflow streamlines method development and sample analysis.
• Enables retrospective data mining for additional qualitative insights without re-acquisition.

Future Trends and Possibilities

• Extension of Tof MRM strategies to other post-translational modifications and low-abundance biomarkers.
• Development of clinical assays for personalized therapy monitoring and diagnostics.
• Integration with advanced informatics, machine learning, and high-throughput workflows to enhance data interpretation.
• Further improvements in instrument duty cycle and multiplexing capabilities for large-scale studies.

Conclusion

The implementation of Tof MRM with enhanced duty cycle on the Xevo MRT Mass Spectrometer delivers a versatile and robust platform for simultaneous qualitative and quantitative analysis of peptide biomarkers in glioblastoma. Comparable sensitivity and linearity to triple quadrupole MRM, coupled with high-resolution accuracy, offer significant advantages in complex sample analysis and biomarker validation.

Reference

1. Poon M T C, Sudlow C L M, Figueroa J D et al. Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Sci Rep. 2020;10:11622. doi:10.1038/s41598-020-68011-4.
2. Qin A, Musket A, Musich P R, Schweitzer J B, Xie Q. Receptor tyrosine kinases as druggable targets in glioblastoma: do signaling pathways matter? Neuro-Oncology Advances. 2021;3(1):vdab133. doi:10.1093/noajnl/vdab133.
3. Tomczyk N, Wallace A, Richardson K, Grzyb A, Wildgoose J. Targeted High Resolution Quantification with Tof-MRM and HD-MRM. Application Brief; Waters Corporation.
4. Hajji N, Garcia-Revilla J, Soto M S et al. Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors. J Clin Invest. 2022;132(6). doi:10.1172/JCI142137.
5. Wang Y et al. The dual role of calnexin on malignant progression and tumor microenvironment in glioma. Sci Rep. 2024;14:30796.
6. Liu Y et al. Calnexin promotes glioblastoma progression by inducing protective mitopagy through the MEK/ERK/BNIP3 pathway. Theranostics. 2025;15(6):2624–2648.